MELANOMA RESEARCH FOUNDATION BREAK… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2010

Legal Domicile

Principal Officer

ANTHONY T HENDRICKSON

Phone

2023479675

Tax Period

2020-04-01 to 2021-03-31

MELANOMA RESEARCH FOUNDATION BREAKTHROUGH CONSORTIUM INC, founded in 2010, is a small nonprofit that reported $320K in total revenue in fiscal year 2020. Revenue decreased 18% compared to the prior year.

Mission

THE MISSION OF THE MELANOMA RESEARCH FOUNDATION BREAKTHROUGH CONSORTIUM, INC. (THE CONSORTIUM) IS TO ACCELERATE THE RESEARCH AND DEVELOPMENT OF THE MOST PROMISING THERAPEUTICS IN MELANOMA IN ORDER TO DELIVER CURATIVE OPTIONS TO PATIENTS. THE CONSORTIUM WILL DEVELOP COLLABORATIVE, MULTI-SECTOR PARTNERSHIPS ACROSS THE BREADTH OF MELANOMA DISCIPLINES - BASIC, TRANSLATIONAL AND CLINICAL SCIENCE - TO EXPEDITE DEVELOPMENT OF COMBINATIONS OF THERAPIES AS WELL AS NOVEL SINGLE AGENTS; SUPPORT PRE-CLINICAL RESEARCH TO FACILITATE RATIONAL COMBINATIONS; CREATE A VIRTUAL ANNOTATED SPECIMEN BIOREPOSITORY; AND IDENTIFY BIOMARKERS THAT HAVE PROGNOSTIC AND PREDICTIVE VALUE OR VALUE AS A NEW THERAPEUTIC TARGET.

Program Service Accomplishments

Program 1

Expenses: $312,789

THE CONSORTIUM SEEKS TO ACCELERATE RESEARCH AND DEVELOPMENT OF THE MOST PROMISING THERAPEUTICS IN MELANOMA IN ORDER TO DELIVER CURATIVE OPTIONS TO PATIENTS. SUCCESS IN THIS ENDEAVOR ALSO FURTHERS THE EXEMPT PURPOSE OF THE MELANOMA RESEARCH FOUNDATION (MRF). IN ORDER TO ACHIEVE ITS MISSION, THE CONSORTIUM WILL DEVELOP COLLABORATIVE, MULTI-SECTOR PARTNERSHIPS ACROSS THE BREADTH OF MELANOMA DISCIPLINES- BASIC, TRANSLATIONAL AND CLINICAL SCIENCE- TO EXPEDITE DEVELOPMENT OF COMBINATION THERAPIES AS WELL AS NOVEL SINGLE AGENTS; SUPPORT PRECLINICAL RESEARCH TO FACILITATE RATIONAL COMBINATIONS; CREATE A VIRTUAL ANNOTATED SPECIMEN BIOREPOSITORY; AND IDENTIFY BIOMARKERS THAT HAVE PROGNOSTIC AND PREDICTIVE VALUE OR VALUE AS NEW THERAPEUTIC TARGETS WHICH REQUIRED THE EXPERTISE OF A MD AND PROJECT MANAGER. IN ADDITION, THE CONSORTIUM'S BOARD OF DIRECTORS AND PARTICIPATING RESEARCH INSTITUTIONS WILL CONDUCT OUTREACH TO MULTI SECTOR PARTNERS WITH AN INTEREST OR INVESTMENT IN MELANOMA RESEARCH TO ENSURE THAT THE CONSORTIUM IS AWARE OF ANY IMPORTANT DEVELOPMENTS OR PROMISING RESEARCH IN THE FIELD OF MELANOMA.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2020)

Revenue Breakdown

Contributions & Grants $320,000

Program Service Revenue $0

Investment Income $0

Other Revenue $0

TOTAL REVENUE $320,000

Expense Breakdown

Grants Paid $300,000

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $312,789

Other Expenses $14,821

TOTAL EXPENSES $314,821

Year-over-Year Comparison

	2020	2019	Change
Revenue	$320,000	$390,534	-0.2%
Expenses	$314,821	$379,543	-0.2%
Net Income	$5,179	$10,991	-0.5%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
STEVE SILVERSTEIN	CHAIRMAN & PRESIDENT	1.00	Officer Director	$0	$0	$0
ANTHONY T HENDRICKSON	TREASURER & CFO	1.00	Officer Director	$0	$0	$0
MICHAEL B ATKINS MD	BOARD MEMBER	1.00	Director	$0	$0	$0
KEITH T FLAHERTY MD	BOARD MEMBER	1.00	Director	$0	$0	$0
JEFFREY E GERSHENWALD MD	BOARD MEMBER	1.00	Director	$0	$0	$0
ALISON MARTIN	BOARD MEMBER	1.00	Director	$0	$0	$0
ZE'EV RONAI PHD	BOARD MEMBER	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2021	$320,000	$314,821	No data	$5,179
2020	$390,534	$379,543	$558,333	$10,991
2019	$375,277	$91,055	$603,844	$284,222

MELANOMA RESEARCH FOUNDATION BREAKTHROUGH CONSORTIUM INC